Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 129

1.

Phosphate binder, ferric citrate, attenuates anemia, renal dysfunction, oxidative stress, inflammation and fibrosis in 5/6 nephrectomized CKD rats.

Jing W, Nunes A, Farzaneh T, Khazaeli M, Lau WL, Vaziri ND.

J Pharmacol Exp Ther. 2018 Aug 9. pii: jpet.118.249961. doi: 10.1124/jpet.118.249961. [Epub ahead of print]

2.

Robotic-assisted laparoscopic repair of rectovesical fistula after Hartmann's reversal procedure.

Sotelo R, Medina LG, Husain FZ, Khazaeli M, Nikkhou K, Cacciamani GE, Landsberger H, Winter M, Hernandez A, Kaiser AM, Gill I.

J Robot Surg. 2018 Jul 30. doi: 10.1007/s11701-018-0854-x. [Epub ahead of print]

PMID:
30062640
3.

Dietary tetrahydrocurcumin reduces renal fibrosis and cardiac hypertrophy in 5/6 nephrectomized rats.

Lau WL, Khazaeli M, Savoj J, Manekia K, Bangash M, Thakurta RG, Dang A, Vaziri ND, Singh B.

Pharmacol Res Perspect. 2018 Feb 19;6(2):e00385. doi: 10.1002/prp2.385. eCollection 2018 Apr.

4.

LCZ696 (Sacubitril/Valsartan), an Angiotensin-Receptor Neprilysin Inhibitor, Attenuates Cardiac Hypertrophy, Fibrosis, and Vasculopathy in a Rat Model of Chronic Kidney Disease.

Suematsu Y, Jing W, Nunes A, Kashyap ML, Khazaeli M, Vaziri ND, Moradi H.

J Card Fail. 2018 Apr;24(4):266-275. doi: 10.1016/j.cardfail.2017.12.010. Epub 2018 Jan 8.

5.

LCZ696 (Sacubitril/valsartan) ameliorates oxidative stress, inflammation, fibrosis and improves renal function beyond angiotensin receptor blockade in CKD.

Jing W, Vaziri ND, Nunes A, Suematsu Y, Farzaneh T, Khazaeli M, Moradi H.

Am J Transl Res. 2017 Dec 15;9(12):5473-5484. eCollection 2017.

6.

Effects of end-stage renal disease and dialysis modalities on blood ammonia level.

Vaziri ND, Khazaeli M, Nunes ACF, Harley KT, Said H, Alipour O, Lau WL, Pahl MV.

Hemodial Int. 2017 Jul;21(3):343-347. doi: 10.1111/hdi.12510. Epub 2016 Nov 1.

7.

Resistant starch alters gut microbiome and metabolomic profiles concurrent with amelioration of chronic kidney disease in rats.

Kieffer DA, Piccolo BD, Vaziri ND, Liu S, Lau WL, Khazaeli M, Nazertehrani S, Moore ME, Marco ML, Martin RJ, Adams SH.

Am J Physiol Renal Physiol. 2016 May 1;310(9):F857-71. doi: 10.1152/ajprenal.00513.2015. Epub 2016 Feb 3.

8.

Lipidomics Biomarkers of Diet-Induced Hyperlipidemia and Its Treatment with Poria cocos.

Miao H, Zhao YH, Vaziri ND, Tang DD, Chen H, Chen H, Khazaeli M, Tarbiat-Boldaji M, Hatami L, Zhao YY.

J Agric Food Chem. 2016 Feb 3;64(4):969-79. doi: 10.1021/acs.jafc.5b05350. Epub 2016 Jan 25.

PMID:
26758241
9.

Dose-dependent deleterious and salutary actions of the Nrf2 inducer dh404 in chronic kidney disease.

Vaziri ND, Liu S, Farzaneh SH, Nazertehrani S, Khazaeli M, Zhao YY.

Free Radic Biol Med. 2015 Sep;86:374-81. doi: 10.1016/j.freeradbiomed.2015.04.022. Epub 2015 Apr 28.

PMID:
25930007
10.

High amylose resistant starch diet ameliorates oxidative stress, inflammation, and progression of chronic kidney disease.

Vaziri ND, Liu SM, Lau WL, Khazaeli M, Nazertehrani S, Farzaneh SH, Kieffer DA, Adams SH, Martin RJ.

PLoS One. 2014 Dec 9;9(12):e114881. doi: 10.1371/journal.pone.0114881. eCollection 2014.

11.

Role of Nrf2 dysfunction in uremia-associated intestinal inflammation and epithelial barrier disruption.

Lau WL, Liu SM, Pahlevan S, Yuan J, Khazaeli M, Ni Z, Chan JY, Vaziri ND.

Dig Dis Sci. 2015 May;60(5):1215-22. doi: 10.1007/s10620-014-3428-4. Epub 2014 Nov 16.

12.

The synthetic triterpenoid RTA dh404 (CDDO-dhTFEA) restores endothelial function impaired by reduced Nrf2 activity in chronic kidney disease.

Aminzadeh MA, Reisman SA, Vaziri ND, Shelkovnikov S, Farzaneh SH, Khazaeli M, Meyer CJ.

Redox Biol. 2013 Oct 31;1:527-31. doi: 10.1016/j.redox.2013.10.007. eCollection 2013.

13.

The synthetic triterpenoid RTA dh404 (CDDO-dhTFEA) restores Nrf2 activity and attenuates oxidative stress, inflammation, and fibrosis in rats with chronic kidney disease.

Aminzadeh MA, Reisman SA, Vaziri ND, Khazaeli M, Yuan J, Meyer CJ.

Xenobiotica. 2014 Jun;44(6):570-8. doi: 10.3109/00498254.2013.852705. Epub 2013 Nov 6.

14.

Oral activated charcoal adsorbent (AST-120) ameliorates chronic kidney disease-induced intestinal epithelial barrier disruption.

Vaziri ND, Yuan J, Khazaeli M, Masuda Y, Ichii H, Liu S.

Am J Nephrol. 2013;37(6):518-25. doi: 10.1159/000351171. Epub 2013 May 15.

15.

Laparoscopic animal surgery for training without sacrificing animals; introducing the rabbit as a model for infantile laparoscopy.

Simforoosh N, Khazaeli M, Nouralizadeh A, Soltani MH, Samzadeh M, Saffarian O, Rahmani J.

J Laparoendosc Adv Surg Tech A. 2011 Dec;21(10):929-33. doi: 10.1089/lap.2011.0308. Epub 2011 Oct 19.

PMID:
22011278
16.

Role of postcircumcision mucosal cuff length in lifelong premature ejaculation: a pilot study.

Hosseini SR, Khazaeli MH, Atharikia D.

J Sex Med. 2008 Jan;5(1):206-9. Epub 2007 Apr 19.

PMID:
17451487
17.

Phase I single-dose study of intracavitary-administered iodine-131-TM-601 in adults with recurrent high-grade glioma.

Mamelak AN, Rosenfeld S, Bucholz R, Raubitschek A, Nabors LB, Fiveash JB, Shen S, Khazaeli MB, Colcher D, Liu A, Osman M, Guthrie B, Schade-Bijur S, Hablitz DM, Alvarez VL, Gonda MA.

J Clin Oncol. 2006 Aug 1;24(22):3644-50.

PMID:
16877732
18.

Use of Surgicel for sealing nephrostomy tract after totally tubeless percutaneous nephrolithotomy.

Aghamir SM, Khazaeli MH, Meisami A.

J Endourol. 2006 May;20(5):293-5.

PMID:
16724896
19.

Intraperitoneal pretarget radioimmunotherapy with CC49 fusion protein.

Buchsbaum DJ, Khazaeli MB, Axworthy DB, Schultz J, Chaudhuri TR, Zinn KR, Carpenter M, LoBuglio AF.

Clin Cancer Res. 2005 Nov 15;11(22):8180-5.

20.

Intraperitoneal radioimmunotherapy with a humanized anti-TAG-72 (CC49) antibody with a deleted CH2 region.

Rogers BE, Roberson PL, Shen S, Khazaeli MB, Carpenter M, Yokoyama S, Brechbiel MW, LoBuglio AF, Buchsbaum DJ.

Cancer Biother Radiopharm. 2005 Oct;20(5):502-13. Erratum in: Cancer Biother Radiopharm. 2005 Dec;20(6):671.

21.

Phase I study of 90Y-CC49 monoclonal antibody therapy in patients with advanced non-small cell lung cancer: effect of chelating agents and paclitaxel co-administration.

Forero A, Meredith RF, Khazaeli MB, Shen S, Grizzle WE, Carey D, Busby E, LoBuglio AF, Robert F.

Cancer Biother Radiopharm. 2005 Oct;20(5):467-78.

PMID:
16248762
22.

Pretargeted radioimmunotherapy (RIT) with a novel anti-TAG-72 fusion protein.

Forero-Torres A, Shen S, Breitz H, Sims RB, Axworthy DB, Khazaeli MB, Chen KH, Percent I, Besh S, LoBuglio AF, Meredith RF.

Cancer Biother Radiopharm. 2005 Aug;20(4):379-90.

PMID:
16114986
23.

Patient-specific dosimetry of pretargeted radioimmunotherapy using CC49 fusion protein in patients with gastrointestinal malignancies.

Shen S, Forero A, LoBuglio AF, Breitz H, Khazaeli MB, Fisher DR, Wang W, Meredith RF.

J Nucl Med. 2005 Apr;46(4):642-51.

24.

Testicular uptake and radiation dose in patients receiving Zevalin and Pretarget CC49Fusion protein.

Shen S, Meredith R, Duan J, Forero A, Breitz H, Khazaeli MB, Brezovich I, LoBuglio A.

Cancer Biother Radiopharm. 2005 Feb;20(1):110-8.

PMID:
15778590
25.

Pharmacokinetics and clinical evaluation of 125I-radiolabeled humanized CC49 monoclonal antibody (HuCC49deltaC(H)2) in recurrent and metastatic colorectal cancer patients.

Xiao J, Horst S, Hinkle G, Cao X, Kocak E, Fang J, Young D, Khazaeli M, Agnese D, Sun D, Martin E Jr.

Cancer Biother Radiopharm. 2005 Feb;20(1):16-26.

PMID:
15778575
26.

Radiation dosimetry of 131I-chlorotoxin for targeted radiotherapy in glioma-bearing mice.

Shen S, Khazaeli MB, Gillespie GY, Alvarez VL.

J Neurooncol. 2005 Jan;71(2):113-9.

PMID:
15690125
27.

Mechanisms of resistance to Erbitux (anti-epidermal growth factor receptor) combination therapy in pancreatic adenocarcinoma cells.

Arnoletti JP, Buchsbaum DJ, Huang ZQ, Hawkins AE, Khazaeli MB, Kraus MH, Vickers SM.

J Gastrointest Surg. 2004 Dec;8(8):960-9; discussion 969-70.

PMID:
15585383
28.

ING-1, a monoclonal antibody targeting Ep-CAM in patients with advanced adenocarcinomas.

de Bono JS, Tolcher AW, Forero A, Vanhove GF, Takimoto C, Bauer RJ, Hammond LA, Patnaik A, White ML, Shen S, Khazaeli MB, Rowinsky EK, LoBuglio AF.

Clin Cancer Res. 2004 Nov 15;10(22):7555-65.

29.

Site-specifically traced drug release and biodistribution of a paclitaxel-antibody conjugate toward improvement of the linker structure.

Safavy A, Georg GI, Vander Velde D, Raisch KP, Safavy K, Carpenter M, Wang W, Bonner JA, Khazaeli MB, Buchsbaum DJ.

Bioconjug Chem. 2004 Nov-Dec;15(6):1264-74.

PMID:
15546192
31.

Pilot study using a humanized CC49 monoclonal antibody (HuCC49DeltaCH2) to localize recurrent colorectal carcinoma.

Agnese DM, Abdessalam SF, Burak WE Jr, Arnold MW, Soble D, Hinkle GH, Young D, Khazaeli MB, Martin EW Jr.

Ann Surg Oncol. 2004 Feb;11(2):197-202.

PMID:
14761924
32.

A novel monoclonal antibody design for radioimmunotherapy.

Forero A, Meredith RF, Khazaeli MB, Carpenter DM, Shen S, Thornton J, Schlom J, LoBuglio AF.

Cancer Biother Radiopharm. 2003 Oct;18(5):751-9.

PMID:
14629823
33.

Expression of CEA, Tag-72, and Lewis-Y antigen in primary and metastatic lesions of ovarian carcinoma.

Chhieng DC, Rodriguez-Burford C, Talley LI, Sviglin H, Stockard CR, Kleinberg MJ, Barnes MN, Partridge EE, Khazaeli MB, Grizzle WE.

Hum Pathol. 2003 Oct;34(10):1016-21.

PMID:
14608535
34.

Comparison of biodistribution, dosimetry, and outcome from clinical trials of radionuclide-CC49 antibody therapy.

Meredith R, Shen S, Macey D, Khazaeli MB, Carey D, Robert F, LoBuglio A.

Cancer Biother Radiopharm. 2003 Jun;18(3):393-404. Erratum in: Cancer Biother Radiopharm. 2003 Aug;18(4):671.

PMID:
12954125
35.

Comparison of methods for predicting myelotoxicity for non-marrow targeting I-131-antibody therapy.

Shen S, Meredith RF, Duan J, Brezovich I, Khazaeli MB, LoBuglio AF.

Cancer Biother Radiopharm. 2003 Apr;18(2):209-15.

PMID:
12804046
36.

A phase I study of anti-kinase insert domain-containing receptor antibody, IMC-1C11, in patients with liver metastases from colorectal carcinoma.

Posey JA, Ng TC, Yang B, Khazaeli MB, Carpenter MD, Fox F, Needle M, Waksal H, LoBuglio AF.

Clin Cancer Res. 2003 Apr;9(4):1323-32.

37.

Synthesis and biological evaluation of paclitaxel-C225 conjugate as a model for targeted drug delivery.

Safavy A, Bonner JA, Waksal HW, Buchsbaum DJ, Gillespie GY, Khazaeli MB, Arani R, Chen DT, Carpenter M, Raisch KP.

Bioconjug Chem. 2003 Mar-Apr;14(2):302-10.

PMID:
12643740
38.

A new monitoring method using solid sorbent media for evaluation of airborne cyclophosphamide and other antineoplastic agents.

Larson RR, Khazaeli MB, Dillon HK.

Appl Occup Environ Hyg. 2003 Feb;18(2):120-31.

PMID:
12519686
39.

Development of an HPLC method for simultaneous analysis of five antineoplastic agents.

Larson RR, Khazaeli MB, Dillon HK.

Appl Occup Environ Hyg. 2003 Feb;18(2):109-19.

PMID:
12519685
40.

A phase I trial of the single-chain immunotoxin SGN-10 (BR96 sFv-PE40) in patients with advanced solid tumors.

Posey JA, Khazaeli MB, Bookman MA, Nowrouzi A, Grizzle WE, Thornton J, Carey DE, Lorenz JM, Sing AP, Siegall CB, LoBuglio AF, Saleh MN.

Clin Cancer Res. 2002 Oct;8(10):3092-9.

41.

A Phase I study of combined modality (90)Yttrium-CC49 intraperitoneal radioimmunotherapy for ovarian cancer.

Alvarez RD, Huh WK, Khazaeli MB, Meredith RF, Partridge EE, Kilgore LC, Grizzle WE, Shen S, Austin JM, Barnes MN, Carey D, Schlom J, LoBuglio AF.

Clin Cancer Res. 2002 Sep;8(9):2806-11.

42.

Improved prediction of myelotoxicity using a patient-specific imaging dose estimate for non-marrow-targeting (90)Y-antibody therapy.

Shen S, Meredith RF, Duan J, Macey DJ, Khazaeli MB, Robert F, LoBuglio AF.

J Nucl Med. 2002 Sep;43(9):1245-53.

43.

Monitoring method for surface contamination caused by selected antineoplastic agents.

Larson RR, Khazaeli MB, Dillon HK.

Am J Health Syst Pharm. 2002 Feb 1;59(3):270-7.

PMID:
11862639
44.

Intraperitoneal radioimmunochemotherapy of ovarian cancer: a phase I study.

Meredith RF, Alvarez RD, Partridge EE, Khazaeli MB, Lin CY, Macey DJ, Austin JM Jr, Kilgore LC, Grizzle WE, Schlom J, LoBuglio AF.

Cancer Biother Radiopharm. 2001 Aug;16(4):305-15.

PMID:
11603001
45.

Phase I study of anti--epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer.

Robert F, Ezekiel MP, Spencer SA, Meredith RF, Bonner JA, Khazaeli MB, Saleh MN, Carey D, LoBuglio AF, Wheeler RH, Cooper MR, Waksal HW.

J Clin Oncol. 2001 Jul 1;19(13):3234-43.

PMID:
11432891
46.

Expression of human endogenous retrovirus k envelope transcripts in human breast cancer.

Wang-Johanning F, Frost AR, Johanning GL, Khazaeli MB, LoBuglio AF, Shaw DR, Strong TV.

Clin Cancer Res. 2001 Jun;7(6):1553-60.

47.

A pilot trial of Vitaxin, a humanized anti-vitronectin receptor (anti alpha v beta 3) antibody in patients with metastatic cancer.

Posey JA, Khazaeli MB, DelGrosso A, Saleh MN, Lin CY, Huse W, LoBuglio AF.

Cancer Biother Radiopharm. 2001 Apr;16(2):125-32.

PMID:
11385959
48.

Quality control of radiolabeled monoclonal antibodies.

Khazaeli MB.

Cancer Biother Radiopharm. 2000 Dec;15(6):529-30. No abstract available.

PMID:
11190485
49.

Synthesis, rhenium-188 labeling and biodistribution studies of a phenolic ester derivative of trisuccin

Safavy A, Khazaeli MB, Mayo MS, Buchsbaum DJ.

Cancer Biother Radiopharm. 1997 Dec;12(6):375-84.

PMID:
10851491
50.

SEREX analysis for tumor antigen identification in a mouse model of adenocarcinoma.

Hampton TA, Conry RM, Khazaeli MB, Shaw DR, Curiel DT, LoBuglio AF, Strong TV.

Cancer Gene Ther. 2000 Mar;7(3):446-55.

Supplemental Content

Loading ...
Support Center